Ports and complications for intraperitoneal chemotherapy delivery

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 2, 2012, Pages 150-159

  Helm, C W ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

intraperitoneal catheter; Intraperitoneal chemotherapy; ovarian cancer

Indexed keywords

CATHETER COMPLICATION; CATHETER INFECTION; CATHETER OCCLUSION; CATHETER REMOVAL; CHEMOTHERAPY; ENDOLEAK; FENESTRATION; HUMAN; INFECTION RISK; INTESTINE PERFORATION; INTESTINE RESECTION; OUTCOME ASSESSMENT; PERITONEAL CATHETER; PERITONITIS; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE OBSTRUCTION; VAGINA DISEASE; VASCULAR ACCESS DEVICE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERS, INDWELLING; CLINICAL COMPETENCE; DEVICE REMOVAL; EQUIPMENT CONTAMINATION; EQUIPMENT FAILURE; FEMALE; GYNECOLOGY; HUMANS; INFUSIONS, PARENTERAL; INTESTINAL PERFORATION; INTESTINE, LARGE; INTESTINE, SMALL; OVARIAN NEOPLASMS; PAIN; PERITONEAL CAVITY; TIME FACTORS;

EID: 83655191912     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2011.03179.x     Document Type: Review

References (39)

1. Dedrick RI, Myers CE, Bungay PM, De Vita VT,. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Canc Treat Rep 1978; 62: 1-11. (Pubitemid 8278518)
2. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al., Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. [see comment] New Engl J Med 1996; 335: 1950-5. (Pubitemid 26428219)
3. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al., Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.[see comment]. J Clin Oncol 2001; 19: 1001-7. (Pubitemid 32176274)
4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al., Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 2006; 354: 34-43. (Pubitemid 43048949)
5. NCI Clinical Announcement. []. Accessed 30 June 2011.
6. Speyer JL, Myers CE,. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res 1980; 74: 264-9.
7. Tenckhoff H, Schechter H,. A bacteriologically safe peritoneal access device. Trans Am Soc Artific Int Org 1968; 14: 181-7.
8. Pfeifle E,. Totally implantable system for peritoneal access. J Clin Oncol 1984; 2: 1277-80.
9. Jenkins J, Sugarbaker PH, Gianola FJ, Myers CE,. Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg, Gynecol & Obstet 1982; 154: 858-62.
10. Myers CE, Collins JM,. Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1983; 1: 395-407. (Pubitemid 14202104)
11. Piccart MJ, Speyer JL, Markman M, ten Bokkel Huinink WW, Alberts D, Jenkins J, et al., Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 1985; 12 (3 Suppl 4): 90-6. (Pubitemid 16222038)
12. Runowicz CD, Dottino PR, Shafir MK, Mark MA, Cohen CJ,. Catheter complications associated with intraperitoneal chemotherapy. Gynecol Oncol 1986; 24: 41-50. (Pubitemid 16104355)
13. Braly P, Doroshow J, Hoff S,. Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Gynecol Oncol 1986; 25: 319-33. (Pubitemid 17197923)
14. Almadrones L, Yerys C,. Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system. Oncol Nurs Forum 1990; 17: 75-80.
15. Davidson SA, Rubin SC, Markman M, Jones WB, Hakes TB, Reichman B, et al., Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 1991; 41: 101-6.
16. Malmstrom H, Carstensen J, Simonsen E,. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 1994; 54: 27-34. (Pubitemid 24239404)
17. Rubin SC, Hoskins WJ, Markman M, Hakes T, Lewis JL Jr,. Long-term access to the peritoneal cavity in ovarian cancer patients. Gynecol Oncol 1989; 33: 46-8. (Pubitemid 19106622)
18. Topuz E, Salihoglu Y, Aydiner A, Saip P, Tas F, Sozen T, et al., Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. J Surg Oncol 2000; 74: 223-6. (Pubitemid 30625464)
19. Nanninga AG, Willemse PHB, Boonstra H, De Vries EGE,. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer. Int J Gynaecol Cancer 1992; 2: 107-10.
20. Sakuragi N, Nakajima A, Nomura E, Noro N, Yamada H, Yamamoto R, et al., Complications Relating to Intraperitoneal Administration of Cisplatin or Carboplatin for Ovarian Carcinoma. Gynecol Oncol 2000; 79: 420-3.
21. Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, et al., An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009; 113: 63-7.
22. Black D, Levine DA, Nicoll L, Chou JF, Iasonos A, Brown CL, et al., Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 2008; 109: 39-42.
23. Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA,. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience. Gynecol Oncol 2009; 114: 420-3.
24. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al., Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III and primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2006; 100: 27-32. (Pubitemid 41815045)
25. Landrum LM, Gold MA, Moore KN, Myers TKN, McMeekin DS, Walker JL,. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol 2008; 108: 342-7. (Pubitemid 351181442)
26. Helm CW, Metzinger DS, Parker LP, Gordinier ME,. Port complications associated with delivery of intraperitoneal chemotherapy for ovarian cancer. Gynecol Oncol [Abstract 294 Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL March 2008]. 2008; 108: S32-155.
27. Lesnock JL, Richard SD, Zorn KK, Krivak TC, Beriwal S, Sukumvanich P, et al., Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol 2010; 116: 345-50.
28. Walker JL,. Intraperitoneal chemotherapy: technique and complications. In:, Helm CW, Edwards RP, editors. Intraperitoneal Cancer Therapy. Totowa, NJ: Humana Press; 2007. pp. 55-69.
29. Arts HJ, Willemse PH, Tinga DJ, de Vries EG, van der Zee AG,. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma. Gynecol Oncol 1998; 69: 32-5. (Pubitemid 28201668)
30. Liou W-S, Teng NN, Chan JK,. A modified technique for insertion of intraperitoneal port for chemotherapy. J Surg Oncol 2005; 90: 247-8. (Pubitemid 40770940)
31. Anaf V, Gangji D, Simon P, Saylam K,. Laparoscopical insertion of intraperitoneal catheters for intraperitoneal chemotherapy. Acta Obstet Gynecol Scand 2003; 82: 1140-5. (Pubitemid 37449383)
32. Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, et al., Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 2001; 81: 77-81. (Pubitemid 32368082)
33. Pendergrass M, Gordinier ME, Parker LP, Metzinger DS, Helm CW,. Retraction of an intraperitoneal chemotherapy port: a case report and literature review. Int J Gynaecol Cancer 2007; 17: 1131-71.
34. Wakefield T, Eckhauser F, Strodel W, Knol J,. Colocutaneous fistula complicating Tenckhoff catheter placement for intraperitoneal chemotherapy. J Surg Oncol 1984; 27: 205-7. (Pubitemid 15200494)
35. Varney RR, Goel R, van Sonnenberg E, Lucas WE, Casola G,. Delayed erosion of intraperitoneal chemotherapy catheters into the bowel. Report of two cases. Cancer 1989; 64: 762-4. (Pubitemid 19185232)
36. Doane L,. Administering intraperitoneal chemotherapy using a peritoneal port. Nurs Clin N Amer 1993; 28: 885-97.
37. Markman M, Walker JL,. Intraperitoneal Chemotherapy of Ovarian Cancer: a Review, With a Focus on Practical Aspects of Treatment. J Clin Oncol 2006; 24: 988-94. (Pubitemid 46638854)
38. Robinson WR, Beyer J,. Factors Affecting the Completion of Intraperitoneal Chemotherapy in Women With Ovarian Cancer. Int J Gynaecol Cancer 2010; 20: 70-4.
39. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, et al., First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003; 90: 637-43.[Erratum appears in Gynecol Oncol 2003 Dec;91(3):662]